BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Observational Program Neo-Penotran® Forte
Completed
- Conditions
- Vaginal CandidiasisBacterial VaginosisTrichomonal Vaginitis
- Interventions
- Drug: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13024
- Registration Number
- NCT01335373
Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT01335256
Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 423
- Registration Number
- NCT01333774
Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 44
- Registration Number
- NCT01332942
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
Phase 3
Completed
- Conditions
- Macular EdemaDiabetes Mellitus
- Interventions
- Biological: VEGF Trap-Eye (BAY86-5321)Procedure: Macular Laser Photocoagulation (Control)
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 406
- Registration Number
- NCT01331681
- Locations
- 🇩🇪
Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Rheinland-Pfalz, Germany
🇮🇹IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
🇫🇷Hopital Lariboisiere, Paris, France
Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America
Phase 3
Withdrawn
- Conditions
- Contraception
- Interventions
- Drug: EE20/DRSP (BAY86-5300)Drug: EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)Drug: EE20/DRSP/L-5-MTHF (BAY98-7071)
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Bayer
- Registration Number
- NCT01331655
Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)
Phase 2
Completed
- Conditions
- Seasonal RhinitisRhinitis
- Interventions
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 539
- Registration Number
- NCT01330017
Essure Transvaginal Ultrasound (TVU) Study
Phase 4
Completed
- Conditions
- Contraceptive Usage
- Interventions
- Device: TVU
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 547
- Registration Number
- NCT01327105
Effect of Rifampin on the Pharmacokinetics of BAY73-4506
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT01322438
Effect of Piroxicam on Ovulation
Phase 2
Completed
- Conditions
- Contraception, Postcoital
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT01320709
© Copyright 2025. All Rights Reserved by MedPath